

- (51) International Patent Classification:
A61K 39/395 (2006.01) G01N 33/68 (2006.01)
C07K 16/40 (2006.01) A61P 27/02 (2006.01)
- (21) International Application Number:
PCT/SG2024/050757
- (22) International Filing Date:
28 November 2024 (28.11.2024)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
10202303390S 30 November 2023 (30.11.2023) SG
- (71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North, Singapore 138632 (SG).
- (72) Inventors: ANG, Koon Hwee; c/o Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis drive, Proteos Building, #03-02, Singapore 138673 (SG). THURA, Min; c/o Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis drive, Proteos Building, #03-02, Singapore 138673 (SG). SU, Xinyi; c/o Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis drive, Proteos Building, #05-15, Singapore 138673 (SG). ZENG, Qi; c/o Institute of Molecular and Cell Biology, A*STAR, 61 Biopolis drive, Proteos Building, #03-02, Singapore 138673 (SG).
- (74) Agent: DAVIES COLLISON CAVE ASIA PTE. LTD.; 10 Collyer Quay, #07-01 Ocean Financial Centre, Singapore 049315 (SG).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

- Declarations under Rule 4.17:
— of inventorship (Rule 4.17(iv))
- Published:
— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))



WO 2025/116819 A1

- (54) Title: METHODS OF TREATING NEOVASCULAR EYE DISEASES
- (57) Abstract: This disclosure relates to the diagnosis and treatment of neovascular eye diseases using PRL3 inhibitors such as PRL3-binding antibodies. Also disclosed herein are methods for detecting neovascular eye diseases such as wet age-related macular degeneration and diabetic retinopathy using PRL3 as a biomarker. The disclosure further relates to a method of enhancing an anti-VEGF therapy in a subject with a neovascular eye disease or condition using a PRL3-binding antibody or antigen-binding fragment thereof.